. Author manuscript; available in PMC: 2016 Mar 24.

Published in final edited form as: Am J Respir Crit Care Med. 2006 Jul 13;174(8):894–900. doi: 10.1164/rccm.200511-1780OC

TABLE 4.

USE OF OPIOIDS, SEDATIVES, NEUROMUSCULAR BLOCKERS, AND CORTICOSTEROIDS^*

	CDW group (N = 74)	Usual weaning group (N = 70)	P value
Sedative agents
Cumulative daily dosage (midazolam-equivalent, mg)
Before inclusion	49 (25–81)	46 (28–81)	0.74
After inclusion	0 (0–8)	0.7 (0–16)	0.14
Opioids
Cumulative daily dosage (fentanyl-equivalent, μg)
Before inclusion	100 (0–795)	170 (0–1312)	0.51
After inclusion	0 (0–50)	0 (0–100)	0.08
Neuromuscular blockers
% of days with NMBs before inclusion	0 (0–0)	0 (0–0)	0.10
% of days with NMBs after inclusion	0 (0–0)	0 (0–0)	0.25
Corticosteroids
% of days with corticosteroids before inclusion	0 (0–33)	0 (0–62)	0.49
% of days with corticosteroids after inclusion	0 (0–0)	0 (0–34)	0.36

Opioids, sedatives, neuromuscular blocking agents (NMB), and corticosteroids used in each group. This table shows the cumulative daily dosages of sedatives per patient (in mg midazolam equivalent) (34) and opioids (in μg fentanyl equivalent) (35) and the percentage of days under neuromuscular blockers and corticosteroids. These data are given for the periods of ventilation before and after study inclusion. Data are expressed as medians (25^th–75^th interquartile range).

CDW denotes computer-driven weaning, NMB neuromuscular blockers